Long-term treatment of venous thromboembolism with low-molecular-weight heparin

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 4, 2000, Pages 326-329

  Monreal, Manuel ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; COUMARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; DRUG EFFICACY; DRUG SAFETY; HUMAN; LONG TERM CARE; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0033913706     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200007000-00013     Document Type: Review

References (17)

1. 1 Hull R, Delmore T, Genton E, et al.: Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979, 301:855-858.
2. 2 Hull R, Delmore T, Carter C, et al.: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982, 306:189-194.
3. 3 Hull R, Hirsh J, Jay R, et al.: Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982, 307:1676-1681.
4. 4 Ginsberg JS, Hirsh J, Turner DC, et al.: Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989; 61:197-203.
5. 5 Pini M, Aiello S, Manotti C, et al.: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994, 72(2):191-197.
6. 6 Das SK, Cohen AT, Edmondson RA, et al.: Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996, 20:521-527.
7. 7 Lopaciuk S, Bielska-Falda H, Noszczyk W, et al.: Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999, 81:26-31. Prospective double-blind study comparing a LMWH with oral anticoagulants in the secondary prevention of venous thromboembolism.
8. 8 Gonzalez-Fajardo JA, Arreba E, Castrodeza J, et al.: Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999, 30:283-292. Prospective double-blind study comparing a LMWH with oral anticoagulants in the secondary prevention of venous thromboembolism.
9. 9 Monreal M, Roncalés FJ, Ruiz J, et al: Secondary prevention of venous thromboembolism: a role for low-molecular-weight heparin. Haemostasis 1999, 28:236-243. Prospective cohort observation study in a large series of patients with venous thromboembolism receiving long-term therapy with either LMWH or oral anticoagulants.
10. 10 The Columbus Investigators: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997, 337:657-662.
11. 11 Simonneau G, Sors H, Charbonnier B, et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. N Engl J Med 1997, 337:663-669.
12. 12 White RH, Beyth RJ, Zhou H, Romano PS: Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999, 107:414-424. Retrospective study evaluating the incidence, time course, and risk factors associated with major bleeeding after discharge in a large series of patients with venous thromboembolism.
13. 13 Kuijer PMM, Hutten BA, Prins MH, Büller HR: Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999, 159:457-460. Prospective study validating a clinical score for the prediction of bleeding in patients with venous thromboembolism receiving oral anticoagulant therapy.
14. 14 Monreal M, Lafoz E, Olive A, et al.: Comparison of subcutaneous unfractioned heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994, 71:7-11.
15. 15 Dunn AS, Coller B: Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med 1999, 106:660-669.
16. 16 Wells PS, Kovacs MJ, Bormanis J, et al.: Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin. Arch Intern Med 1998, 158:1809-1812.
17. 17 Baron RM, Goldhaber SZ: Deep venous thrombosis: outpatient management is now FDA approved. J Thromb Thrombolys 1999, 7:113-122.